Drugs / 06Benzylguanine
06Benzylguanine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00272870 | Dec 2005 → Dec 2008 | anaplastic astrocytoma, glioblastoma | Children's Hospital Medical Center, Cincinnati | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 06Benzylguanine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00272870 ↗ |
| Known as | 06BG | “The idea is to make tumor cells more sensitive to a chemotherapy agent, Temozolomide, by using 06Benzylguanine (06BG).” NCT00272870 ↗ |
| Known as | O6-Benzylguanine | “To overcome TEM resistance, in this study we will add the chemotherapy sensitizing drug O6-Benzylguanine (BG).” NCT00272870 ↗ |